Targeting ganglioneuromas with mTOR inhibitors.
AKT
Ganglioneuroma
mTOR inhibitor
zebrafish model
Journal
Molecular & cellular oncology
ISSN: 2372-3556
Titre abrégé: Mol Cell Oncol
Pays: United States
ID NLM: 101642411
Informations de publication
Date de publication:
10 Jan 2021
10 Jan 2021
Historique:
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink large ganglioneuromas prior to surgical resection.
Identifiants
pubmed: 33553609
doi: 10.1080/23723556.2020.1856621
pii: 1856621
pmc: PMC7849689
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1856621Subventions
Organisme : NCI NIH HHS
ID : K08 CA245251
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210064
Pays : United States
Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Eur J Pediatr Surg. 2011 Jan;21(1):33-7
pubmed: 20954104
Cancer Res. 2009 Jun 15;69(12):5057-64
pubmed: 19491266
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
J Cell Biol. 2005 Dec 19;171(6):1023-34
pubmed: 16365168
BMC Cancer. 2016 Jul 27;16:542
pubmed: 27465021
Cancer Cell. 2012 Mar 20;21(3):362-73
pubmed: 22439933
Radiographics. 2002 Jul-Aug;22(4):911-34
pubmed: 12110723
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32728700